SCHEMBL304242

SCHEMBL304242

CCCCC[CH]c1cccc2ccccc12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHAT P28329 3/20 0.50
CNR1 P21554 2/20 0.50
GAA P10253 5/20 0.39
KDM4E B2RXH2 5/20 0.39
NPC1 O15118 4/20 0.39
ALDH1A1 P00352 4/20 0.39
HTT P42858 4/20 0.39
RAB9A P51151 4/20 0.39
SMN1; SMN2 Q16637 4/20 0.39
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
TDP1 Q9NUW8 2/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
HTR1B P28222 1/20 0.39
GLA P06280 1/20 0.39
RCE1 Q9Y256 1/20 0.39
MTNR1A P48039 1/20 0.38
MTNR1B P49286 1/20 0.38
NPSR1 Q6W5P4 2/20 0.38
LMNA P02545 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL302714 0.98 CHAT (0.52) CHATCNR1GAAKDM4ENPC1
SCHEMBL303905 0.98 CHAT (0.52) CHATCNR1GAAKDM4ENPC1
SCHEMBL304715 0.98 CHAT (0.52) CHATCNR1GAAKDM4ENPC1
SCHEMBL302934 0.98 CHAT (0.52) CHATCNR1GAAKDM4ENPC1
SCHEMBL304218 0.98 CHAT (0.52) CHATCNR1GAAKDM4ENPC1
SCHEMBL303925 0.98 CHAT (0.52) CHATCNR1GAAKDM4ENPC1
SCHEMBL303704 0.98 CHAT (0.52) CHATCNR1GAAKDM4ENPC1
SCHEMBL303784 0.98 CHAT (0.52) CHATCNR1GAAKDM4ENPC1
SCHEMBL302668 0.98 CHAT (0.52) CHATCNR1GAAKDM4ENPC1
SCHEMBL303607 0.98 CHAT (0.52) CHATCNR1GAAKDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 396 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116848094-A Tertiary amine lipid compounds and uses thereof 华南理工大学 2023-10-03 CN claimed
WO-2023125184-A1 TERTIARY AMINE LIPID COMPOUND AND USE THEREOF 华南理工大学 2023-07-06 WO claimed
CN-1738829-B New 2',5'-oligoadenylic acid analog SANKYO CO 2012-11-28 CN claimed
US-20240239745-A1 METHOD FOR SYNTHESIZING BILIRUBIN Bilix Co., Ltd. (KR) 2024-07-18 US disclosed
EP-4234609-B1 METHODS FOR PURIFICATION, DETECTION AND QUANTIFICATION OF RESIDUAL PEI-BASED TRANSFECTION REAGENTS POLYPLUS TRANSFECTION (FR) 2024-07-17 EP disclosed
EP-4375280-A1 METHOD FOR SYNTHESIZING BILIRUBIN Bilix Co., Ltd. (KR) 2024-05-29 EP disclosed
EP-4371985-A1 METHOD FOR SYNTHESIZING BILIRUBIN Bilix Co., Ltd. (KR) 2024-05-22 EP disclosed
EP-4371984-A1 METHOD FOR SYNTHESIZING BILIRUBIN Bilix Co., Ltd. (KR) 2024-05-22 EP disclosed
EP-4019607-B1 ELECTROCHROMIC COMPOUNDS AND OPTICAL ARTICLES CONTAINING THEM ESSILOR INT (FR) 2024-05-15 EP disclosed
CN-117881673-A Synthesis method of bilirubin 株式会社毕丽斯 2024-04-12 CN disclosed
CN-117836290-A Synthesis method of bilirubin 株式会社毕丽斯 2024-04-05 CN disclosed
EP-0501656-A2 New benzene derivatives having (NGF) production-promoting activity Sankyo Company Limited (JP) 1992-09-02 EP disclosed
EP-0498680-A1 New beta-amino-alpha-hydroxycarboxylic acids and their use Sankyo Company Limited (JP) 1992-08-12 EP disclosed
WO-1991014719-A2 IMPROVED POLYBUTENE PROCESS EXXON CHEMICAL PATENTS INC. (US) 1991-10-03 WO disclosed
US-4952739-A ORGANOALUMINUM AND HYDROGEN CHLORIDE POLYMERIZATION CATALYST EXXON CHEMICAL PATENTS INC. (US) 1990-08-28 US disclosed
US-4935576-A Polybutene process EXXON CHEMICAL PATENTS INC. (US) 1990-06-19 US disclosed
EP-0370805-A2 Improved polybutene process EXXON CHEMICAL PATENTS INC. (US) 1990-05-30 EP disclosed
EP-0367385-A2 Improved organo-A1-chloride catalyzed poly-n-butenes process EXXON CHEMICAL PATENTS INC. (US) 1990-05-09 EP disclosed
US-4427640-A Sequential process for extraction and recovery of vanadium and uranium from wet process acids KERR-MCGEE CHEMICAL CORPORATION (US) 1984-01-24 US disclosed
US-4329350-A VASODILATORS RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) 1982-05-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240239745-A1 METHOD FOR SYNTHESIZING BILIRUBIN CYP7A1, UGT1A3, UGT1A1 CHAT 1906/4885CNR1 3189/4885GAA 724/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.